R1 RCM INC. Insider Trading for August 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in R1 RCM INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in R1 RCM INC. for August 2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.80 | 12,500 | 22,500 | 50,000 | 37.5 K to 50 K (+33.33 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.80 | 1,500 | 2,700 | 37,500 | 36 K to 37.5 K (+4.17 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.81 | 14,500 | 26,245 | 36,000 | 21.5 K to 36 K (+67.44 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.81 | 1,500 | 2,715 | 21,500 | 20 K to 21.5 K (+7.50 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.80 | 10,000 | 17,975 | 20,000 | 10 K to 20 K (+100.00 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.80 | 7,800 | 14,040 | 10,000 | 2.2 K to 10 K (+354.55 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.79 | 500 | 895 | 2,200 | 1.7 K to 2.2 K (+29.41 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.77 | 500 | 885 | 1,700 | 1.2 K to 1.7 K (+41.67 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.79 | 500 | 893 | 1,200 | 700 to 1.2 K (+71.43 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.77 | 100 | 177 | 700 | 600 to 700 (+16.67 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.79 | 500 | 895 | 600 | 100 to 600 (+500.00 %) |
| Aug 17 2016 | AH | Accretive Health, ... | HENNEMAN JOHN B III | Director | Buy | P | 1.78 | 100 | 178 | 100 | 0 to 100 |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.72 | 6,201 | 10,666 | 2,450,000 | 2.4 M to 2.5 M (+0.25 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.71 | 3,799 | 6,496 | 2,443,799 | 2.4 M to 2.4 M (+0.16 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.72 | 1,600 | 2,752 | 2,440,000 | 2.4 M to 2.4 M (+0.07 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.72 | 150,000 | 258,000 | 2,438,400 | 2.3 M to 2.4 M (+6.55 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.70 | 15,900 | 27,030 | 2,288,400 | 2.3 M to 2.3 M (+0.70 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.69 | 2,500 | 4,225 | 2,272,500 | 2.3 M to 2.3 M (+0.11 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.54 | 4,400 | 6,776 | 2,270,000 | 2.3 M to 2.3 M (+0.19 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.52 | 5,000 | 7,600 | 2,265,600 | 2.3 M to 2.3 M (+0.22 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.52 | 100 | 152 | 2,260,600 | 2.3 M to 2.3 M (0.00 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.52 | 500 | 758 | 2,260,500 | 2.3 M to 2.3 M (+0.02 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.51 | 2,300 | 3,473 | 2,260,000 | 2.3 M to 2.3 M (+0.10 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.51 | 2,500 | 3,775 | 2,257,700 | 2.3 M to 2.3 M (+0.11 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.51 | 2,500 | 3,775 | 2,255,200 | 2.3 M to 2.3 M (+0.11 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.51 | 100 | 151 | 2,252,700 | 2.3 M to 2.3 M (0.00 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.51 | 100 | 151 | 2,252,600 | 2.3 M to 2.3 M (0.00 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.51 | 2,000 | 3,020 | 2,252,500 | 2.3 M to 2.3 M (+0.09 %) |
| Aug 11 2016 | AH | Accretive Health, ... | SHULMAN STEVEN J | Director | Buy | P | 1.51 | 500 | 753 | 2,250,500 | 2.3 M to 2.3 M (+0.02 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.55 | 20,000 | 31,000 | 200,000 | 180 K to 200 K (+11.11 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.54 | 1,000 | 1,540 | 180,000 | 179 K to 180 K (+0.56 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.53 | 5,000 | 7,650 | 179,000 | 174 K to 179 K (+2.87 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.80 | 25,001 | 45,002 | 174,000 | 149 K to 174 K (+16.78 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.79 | 5,599 | 10,022 | 148,999 | 143.4 K to 149 K (+3.90 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.51 | 4,500 | 6,795 | 143,400 | 138.9 K to 143.4 K (+3.24 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.76 | 1,300 | 2,288 | 138,900 | 137.6 K to 138.9 K (+0.94 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.74 | 2,500 | 4,350 | 137,600 | 135.1 K to 137.6 K (+1.85 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.73 | 10,100 | 17,473 | 135,100 | 125 K to 135.1 K (+8.08 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.72 | 10,000 | 17,200 | 125,000 | 115 K to 125 K (+8.70 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.53 | 13,100 | 20,043 | 115,000 | 101.9 K to 115 K (+12.86 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.51 | 1,200 | 1,812 | 101,900 | 100.7 K to 101.9 K (+1.19 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.51 | 35,000 | 52,850 | 100,700 | 65.7 K to 100.7 K (+53.27 %) |
| Aug 11 2016 | AH | Accretive Health, ... | MANDL ALEX | Director | Buy | P | 1.51 | 65,700 | 99,207 | 65,700 | 0 to 65.7 K |
| Aug 11 2016 | AH | Accretive Health, ... | RICAURTE CHRISTOPHER SIMON | Chief Financial Off ... | Buy | P | 1.56 | 100,000 | 156,000 | 311,902 | 211.9 K to 311.9 K (+47.19 %) |
| Aug 11 2016 | AH | Accretive Health, ... | FLANAGAN JOSEPH GERARD | President, CEO and ... | Buy | P | 1.56 | 100,000 | 156,000 | 1,431,814 | 1.3 M to 1.4 M (+7.51 %) |
| Aug 04 2016 | AH | Accretive Health, ... | FLANAGAN JOSEPH GERARD | President, CEO and ... | Payment of Exercise | F | 1.90 | 3,809 | 7,237 | 1,331,814 | 1.3 M to 1.3 M (-0.29 %) |